Meeting
2017 Gastrointestinal Cancers Symposium
Impact of nab-paclitaxel-based second-line chemotherapy on the outcomes of pancreatic cancer.
Authors
Neelakanta Dadi
Indiana University Health, Indianapolis, IN
Neelakanta Dadi , Safi Shahda , Bert H. O'Neil , Amikar Sehdev
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 483)
DOI
10.1200/JCO.2017.35.4_suppl.483
Abstract #
483
Poster Bd #
N1
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Ciprofloxacin plus gemcitabine-based chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma: A pilot study of microbiome manipulation.
First Author: Seng Wee Cheo
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Targeted therapy (TT) in patients with KRAS wildtype (WT) pancreatic ductal adenocarcinoma (PDAC) produces durable response.
First Author: Maahum Mehdi
Poster
2020 Gastrointestinal Cancers Symposium
A phase II study of nab-paclitaxel plus ramucirumab for the second-line treatment of patients with metastatic gastroesophageal cancer.
First Author: Johanna C. Bendell
Poster
2020 Gastrointestinal Cancers Symposium
An institutional series of early-onset pancreatic cancer (EOPC): Clinical outcomes and genetic and supportive care referral patterns.
First Author: Kunal C. Kadakia